Figure 4
Figure 4. c-Jun is enriched in extranodal lymphoma. (A) Positron emission tomography/computed tomography (PET/CT) images from patients with different lymphoma localization. Patients #1 and #2 had only nodal sites of involvement; representative images are shown. Patient #3 had multifocal extranodal involvement in the bone marrow in the spine, as shown in sagittal images. Patient #4 had multiple extranodal sites of involvement, including bone marrow, subcutaneous tissues, and perineural spread. Expression of p-c-Jun (Ser73) in DLBCL tumor tissues from these patients was determined by immunohistochemistry; representative images are shown (×500). (B-D) Expression of c-Jun was stratified by the number of extranodal sites using microarray data available in a public repository (GSE10846). Log2 median-centered intensities of c-Jun (probe 201465_s) in 296 cases with a known number of extranodal sites were obtained by using Oncomine v4.5 (www.oncomine.org). Patients diagnosed with the ABC or GCB subtypes of DLBCL were analyzed in (C) and (D), respectively. Statistical significance was evaluated by using two-tailed Student t test. ****P < .0001; ***P < .001; **P < .01; *P < .05.

c-Jun is enriched in extranodal lymphoma. (A) Positron emission tomography/computed tomography (PET/CT) images from patients with different lymphoma localization. Patients #1 and #2 had only nodal sites of involvement; representative images are shown. Patient #3 had multifocal extranodal involvement in the bone marrow in the spine, as shown in sagittal images. Patient #4 had multiple extranodal sites of involvement, including bone marrow, subcutaneous tissues, and perineural spread. Expression of p-c-Jun (Ser73) in DLBCL tumor tissues from these patients was determined by immunohistochemistry; representative images are shown (×500). (B-D) Expression of c-Jun was stratified by the number of extranodal sites using microarray data available in a public repository (GSE10846). Log2 median-centered intensities of c-Jun (probe 201465_s) in 296 cases with a known number of extranodal sites were obtained by using Oncomine v4.5 (www.oncomine.org). Patients diagnosed with the ABC or GCB subtypes of DLBCL were analyzed in (C) and (D), respectively. Statistical significance was evaluated by using two-tailed Student t test. ****P < .0001; ***P < .001; **P < .01; *P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal